Skip to main content

hmpl-760

Generic: BTK Inhibitor HMPL-760

hmpl-760: 3 clinical trials tracked.

hmpl-760 evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about hmpl-760, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trials (3)

An Open-Label, Randomized, Four-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food and Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of HMPL-760 Capsules in Healthy Participants

NCT07643272·Phase 1·HCM
Active, not recruiting

Primary endpoint: AUC 0-last

InterventionalRandomizedopen24 enrolledStarted 2026-06Completion 2026-121 site · ChinaHutchmed

A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT07409428·Phase 3·HCM
Recruiting

Primary endpoint: Progression-free survival (PFS)

InterventionalRandomizedquadruple240 targetStarted 2026-03Completion 2028-1250 sites · ChinaHutchmed

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05190068·Phase 1·HCM
Completed

Primary endpoint: DLTs

Interventionalopen89 enrolledStarted 2022-01Completion 2025-0122 sites · ChinaHutchmed